<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055403</url>
  </required_header>
  <id_info>
    <org_study_id>M201-A-CT-001</org_study_id>
    <nct_id>NCT03055403</nct_id>
  </id_info>
  <brief_title>First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Continuous Intravenous Injection, Dose Escalation, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of M201-A in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuji KUMAGAI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aetas Pharma Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kitasato University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I first-in-human is designed to evaluate the safety, tolerability and
      pharmacokinetics of single ascending doses of M201-A administered by single continuous
      intravenous injection in Healthy Japanese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not Provided
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Throughout the study duration (up to day8)</time_frame>
    <description>adverse events, serious adverse events, physical examinations, vital sign measurements, 12-lead ECGs, Holter ECG, clinical laboratory safety tests (including hematology, chemistry, and urinalysis), recording of concomitant medications and procedures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A</time_frame>
    <description>Observed maximum plasma concentration (Cmax) of M201-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Tmax</measure>
    <time_frame>Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A</time_frame>
    <description>Time to Cmax (Tmax) of M201-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-24</measure>
    <time_frame>Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to 24hour of M201-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-t</measure>
    <time_frame>Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A</time_frame>
    <description>-Area under the plasma concentration-time curve calculated from time zero to the last measured time point (AUC0-t) of M201-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-∞</measure>
    <time_frame>Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A</time_frame>
    <description>Area under the plasma concentration-time curve calculated from time zero to infinity (AUC0-∞) of M201-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-t1/2</measure>
    <time_frame>Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A</time_frame>
    <description>Elimination half-life (t1/2) of M201-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-CL</measure>
    <time_frame>Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A</time_frame>
    <description>Apparent clearance of drug from plasma (CL) of M201-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Vd</measure>
    <time_frame>Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A</time_frame>
    <description>Apparent volume of distribution during the terminal phase (Vd) of M201-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-E0-24</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Amount of drug excreted in urine from time zero to 24hour of M201-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Ae</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Urinary excretion rate of M201-A</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>M201-A Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Substance: M201-A Route of administration: continuous intravenous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Placebo for M201-A Route of administration: continuous intravenous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M201-A Injection</intervention_name>
    <description>Active Substance: M201-A Route of administration: continuous intravenous injection</description>
    <arm_group_label>M201-A Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline Placebo for M201-A Route of administration: continuous intravenous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must satisfy the following criteria to be enrolled in the study:

          -  Japanese Healthy Male subjects

          -  Age 20 to less than 40 years of age

          -  Body Mass Index (BMI) of 18.5 to less than 25.0 kg/m2

          -  Written informed consent must be obtained on a voluntary basis before any assessment
             is performed.

        Exclusion Criteria:

        The presence of any of the following will exclude a subject from enrollment:

          -  Presence or past medical history of hepatic impairments, renal impairments,
             cardiovascular disease, gastrointestinal disease and others which are inappropriate
             for participating in this clinical trial

          -  Past medical history of cancer, cerebral infarction or cardiac infarction

          -  Presence or past medical history of allergic reactions or idiosyncrasies to food,
             medicinal substance and metallic materials

          -  QTcF &gt; 450ms at the screening examination

          -  NT-proBNP &gt; 125 pg/mL at the screening examination

          -  Any risk factors of Torsades de Pointes including such as heart failure, hypokalemia,
             long QT interval syndrome due to family medical history
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mika Maeda</last_name>
    <phone>81-42-778-8111</phone>
    <phone_ext>8242</phone_ext>
    <email>m-maeda@kitasato-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Center, Kitasato University Hospital, THE KITASATO INSTITUTE</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mika Maeda</last_name>
      <phone>81-42-778-8111</phone>
      <phone_ext>8242</phone_ext>
      <email>m-maeda@kitasato-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Kenji Kobayashi</last_name>
      <phone>81-42-778-8111</phone>
      <phone_ext>7845</phone_ext>
      <email>kobaken@kitasato-u.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Yuji Kumagai</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masako Aso</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoshiya Ito</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hideki Amano</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuko Shibata</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masako Nagashima</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chie Kurashige</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomoyoshi Inoue</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sakiko Yamane</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomohiro Betto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junya Ako</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hidehira Fukaya</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Kishihara</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akira Satoh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naruya Ishizue</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamami Fujiishi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tazuru Igarashi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuichiro Iida</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hironori Nakamura</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teppei Fujita</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kazuhiro Fujiyoshi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Toyoji Kaida</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takuya Hashimoto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryota Kakizaki</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teruyoshi Nemoto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kitasato University</investigator_affiliation>
    <investigator_full_name>Yuji KUMAGAI</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

